For more information, visit www.miltenyibiotec.com/applic... Human pluripotent stem cells (PSCs) and their derivatives hold great potential in regenerative cell therapies. Establishing GMP-compliant PSC banks is a critical step in the manufacturing processes of PSC-derived cell products.
In this webinar, Chao Sheng will introduce the established workflows from Miltenyi Biotec for automated and closed human PSC expansion and differentiation using the CliniMACS Prodigy® Adherent Cell Culture process and the iPS-Brew GMP Medium.
Meanwhile, Camie Chan will discuss how cell therapies have emerged as a promising next-generation modality for many incurable diseases. In her talk on “Establishing the first southern Chinese haplobank of clinical-grade hiPSCs”, she will illustrate how Xellera has established the first commercial cGMP facility for cell and gene products in Hong Kong. By analyzing the HLA diversity of the southern Chinese population, Xellera has identified donors that are homozygous for the most frequent HLA-A,B,C, and DRB1 combination. The top seven human induced pluripotent stem cell (hiPSC) lines of the haplobank are expected to cover approximately 30% of the southern Chinese population, offering an off-the-shelf approach for allogeneic transplantation of hiPSC-derived cell therapies.
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries - all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.